PARIS, Feb. 9 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has successfully completed its tender offer for all outstanding shares of common stock of Chattem, Inc. (NASDAQ:CHTT) . [more]
LONDON, Feb. 9 /PRNewswire/ -- Biomarker analysis market has excellent growth potential. The 'omics' revolution of the last decade has ensured that the field of biomarker research will test the frontiers of biomedical research in the coming years. Biomarkers have a multitude of applications such as early disease detection, identifying potential drug targets, predicting patient response to medication and accelerating clinical trials. [more]
NEW YORK, Feb. 9 /PRNewswire/ -- Intrasphere Technologies, a leading consulting and solutions firm that provides business-focused services and software solutions to Life Sciences organizations, announced today the launch of PharmaCM CTR Express for Clinical Trial Registration. PharmaCM CTR Express is a comprehensive clinical trial registration and results disclosure solution that is fully pre-configured for quick deployment. Offered as Software as a Service (SaaS), the solution is a fully validated application, hosted by Intrasphere and updated regularly to keep current with rapidly evolving trial disclosure requirements. [more]
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its research and diagnostic antibodies unit AbD Serotec will expand its sales organization in Düsseldorf to support growth in continental and eastern Europe as well as in Asia. Today's official opening ceremony was performed by Friedrich G. Conzen, major of Düsseldorf. [more]
Milan, Italy, 9 February 2010 - BioXell S.p.A. (SIX Swiss Exchange: BXLN) today announced that, on 8 February 2010, which is the end of the offer period, Cosmo Pharmaceuticals S.p.A. holds 94.773 percent of the shares, respectively voting rights of BioXell S.p.A, Milano. This announcement is made in connection with the recommended public tender offer of Cosmo Pharmaceuticals S.p.A. for the shares of BioXell (see www.cosmopharmaceuticals.com). An additional acceptance period begins on 15 February 2010 and ends on 26 February 2010. [more]
(BUSINESS WIRE)--Feb 8, 2010 - BioNJ The feature film “Extraordinary Measures” is inspired by the true story of Amicus President and CEO John Crowley, who bucked conventional wisdom and risked his family's fortune to pursue a cure for his children's life-threatening disease. [more]
EMERYVILLE, Calif.--(BUSINESS WIRE)--Feb 8, 2010 - KineMed, Inc. a translational and personalized medicine development company, today announced a broadening of its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) in the area of Alzheimer's disease and other neurodegenerative conditions. This agreement builds on the original collaboration between the two companies begun in June 2009. [more]
SAN DIEGO--(BUSINESS WIRE)--Feb 8, 2010 - AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a strategic collaboration with Merck, through an affiliate, to develop novel antibody therapeutics to a specified disease target. [more]
NORWALK, Conn.--(BUSINESS WIRE)--Feb 8, 2010 - IMS Health (NYSE: RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced that its stockholders approved the proposal to adopt the merger agreement providing for its acquisition by entities created by certain affiliates of TPG Capital, L.P. (“TPG”) and the CPP Investment Board (“CPPIB”). [more]
PRINCETON, NJ, Feb. 8 /PRNewswire-FirstCall/ -- NUCRYST Pharmaceuticals Corp. ("Nucryst") (TSX:NCS / NASDAQ:NCST) today is pleased to announce the completion of the previously announced amalgamation (the "Amalgamation") of Nucryst with 1499642 Alberta Ltd. ("1499642"), a wholly-owned subsidiary of the Westaim Corporation ("Westaim"), pursuant to an Amalgamation Agreement dated as of November 10, 2009, as amended (the "Amalgamation Agreement"). The resolution approving the Amalgamation was approved at the Special Meeting of Shareholders reconvened and concluded on February 8, 2010 and the Amalgamation was effected by the filing of Articles of Amalgamation thereafter. [more]
HARBIN, China, Feb. 8 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheet: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), announced today that it has filed its annual report on Form 10-K for the fiscal year ended October 31, 2009 on time. [more]
Gothenburg, Sweden – 08.02.2010 Denator AB announced today that the company has signed an exclusive distribution agreement with Basel-based Bucher Biotec AG. Bucher will handle sales and service in Switzerland for Denator’s heat inactivation technology, Stabilizor T1. [more]
Reykjavik, Iceland, 8 February 2010 ? Actavis Group, the international generic pharmaceuticals company, today announced plans to expand its manufacturing site in Iceland, increasing capacity at the site by 50%. Fifty new jobs will be created as a result. [more]
BRISBANE, Calif.--(BUSINESS WIRE)--Feb 5, 2010 - Addressing the importance of job creation, BayBio and Assemblyman Jerry Hill announced legislation to retain and attract California's second largest employing industry during a press conference at an R&D lab in Northern California. [more]
MONTREAL, Feb. 5 /PRNewswire-FirstCall/ -- Haemacure Corporation (TSX:HAE) announces that it has today obtained a first extension until March 22, 2010 of the delay within which to make a proposal pursuant to the notice of intention to make a proposal to its creditors it filed on January 8, 2010 under the Bankruptcy and Insolvency Act (Canada). This extension is intended to allow Haemacure to complete a call for tenders for the sale of its assets, close a sale transaction with the successful tenderer, seek the required approvals for the transaction and proposal to creditors, and execute the proposal. [more]
OCEANSIDE, Calif.--(BUSINESS WIRE)--Feb 5, 2010 - International Stem Cell Corporation, www.internationalstemcell.com, announced today that its new cell production facility has passed final building inspection, which will enable development and manufacturing of the company and its partners' clinical-grade stem cell products. [more]
LONDON, February 4/PRNewswire/ -- A major centre created by the Medical Research Council (MRC) and MRC Technology (MRCT) in order to fast-track the discovery and development of novel drugs, opens its first call for targets today. [more]
SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC:VXGN) (BULLETIN BOARD: VXGN) announced preliminary results of the vote from its special stockholder meeting held on February 3, 2010. [more]
CHANGCHUN, China and LOS ANGELES, Feb. 4 /PRNewswire-Asia/ -- China Yongxin Pharmaceutical, Inc. (OTC:CYXN) (BULLETIN BOARD: CYXN) (the Company), one of the fastest growing, vertically-integrated health products companies in China, today announced it has engaged Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ:RODM) , as the Company's financial advisor to develop financing options in support of the Company's growth plan and provide guidance on meeting listing standards with NASDAQ or AMEX. [more]
Mergers & Acquisitions, Partnerships, & Collaborations 2010 – Review and Outlook
This PharmaLive Special Report analyzes the healthcare industry’s M&As of 2009, providing a comprehensive listing of companies’ M&A activity and detailing the top 20 deals within each of the Pharmaceutical, Biotechnology, Specialty, and Medical Device sectors, and previews potential M&A activity within the healthcare arena for 2010.
The introductory rate of $395 expires February 17, 2010.
